Abstract Library

#3800 Correlation between early response and lesion dosimetry in patients with advanced neuroendocrine tumor (NET) treated with radioligand therapy (RLT)

Introduction: The identification of predictive parameters of response to radioligand therapy (RLT) in NET patients is essential in order to avoid futile therapy toxicities. The relation between the tumor absorbed dose and therapy response has so far not been established.

Conference:

Presenting Author: Durmo R

Authors: Durmo R, Fioroni F, Grassi E, Coruzzi C, Giulia B,

Keywords: RLT, Dosimetry,

#3189 Real-world outcomes of patients with neuroendocrine liver metastases treated with trans-arterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study

Introduction: Trans-arterial radioembolization (TARE) is a treatment option for patients with liver dominant metastases from neuroendocrine tumors (mNET). The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European prospective multi-centre observational study conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Helmberger T

Authors: Helmberger T, Schaefer N, Pech M, Pfammatter T, Maleux G,

Keywords: liver metastases, observational study, yttrium-90, trans-arterial radioembolization, registry, therapeutic embolization, SIRT,

#1814 Predictors of Outcome in Patients Treated with Peptide Radio-Labelled Receptor Target Therapy (PRRT)

Introduction: The efficacy of PRRT has been demonstrated in patients with well differentiated NETS. The NETTER-01 study demonstrated disease stabilisation or partial response in approximately 80% of patients. However, more studies are needed to identify predictors of response

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Demetriou G

Authors: Demetriou G, Diamantopoulos L, Devakumar H, Popat R, Koffas A,

Keywords: PRRT, Y90, Lu-177,

#1098 177Lu Dotatate vs Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit

Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tipping J

Authors: Page E, Tipping J, Birch E, Hamilton D, Manoharan P,

Keywords: PRRT, Toxicity, Audit, RM Dose,

#550 Predictors of Survival Following Y90 DOTATOC/DOTATATE Therapy

Introduction: Y90-DOTATATE and Y90-DOTATOC are established treatments for patients with advanced neuroendocrine tumours. Outcomes associated with improved survival following therapy are still unclear.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Gilbert T, Mckane G, Banks M, Poston G, Vora J,

Keywords: Y90 DOTATOC/DOTATATE, survival,